前列腺癌肝转移在11C-胆碱PET/CT上的表现:一项多中心回顾性分析
该多中心回顾性分析纳入542例根治治疗后生化复发的前列腺癌患者,共分析742次11C-胆碱PET/CT,按肝低密度病灶与示踪剂摄取分为五组。结果显示肝转移(D-E组)与骨病灶显著相关(p=0.00193),而与PSA、环形SUVmax、局部复发、阳性淋巴结无显著关联。作者认为复发前列腺癌肝转移可能较常见,核医学医师应仔细分析肝脏示踪剂分布。
要点
- 542例复发前列腺癌患者中,18例(3.3%)经病理或影像/临床证实为肝转移(E组)。
- 肝转移(D-E组)与骨病灶显著相关(p=0.00193),与PSA、环形SUVmax等无显著关联。
- 作者认为胆碱PET/CT上肝脏示踪剂分布改变可被误认为单纯囊肿,需仔细分析。
核心结论
- 作者认为复发前列腺癌中肝转移可能较常见,但真实发生率评估需更多研究。
- 作者指出胆碱PET/CT虽存在技术局限,但可显示肝脏示踪剂分布改变,结合高触发PSA、伴随骨病灶或随时间变化时可被怀疑。
- 作者认为在此临床情境下,核医学医师对肝脏示踪剂分布(摄取增高或减低)进行准确分析是必须的。
研究设计与样本
- 多中心回顾性分析,回顾性纳入542例根治治疗(手术和/或放疗)后生化复发的前列腺癌患者。
- 排除合并第二肿瘤或其他良性肝脏疾病的患者,所有患者均行11C-胆碱PET/CT标准再分期检查。
- 分析CT图像评估低密度病灶及PET图像相应示踪剂摄取,按肿瘤学病史分为A至E五组。
- 542例中140例曾行多次11C-胆碱PET/CT,共分析742次扫描。
主要发现
- 456/542例(84.1%)肝脏在低剂量CT和PET上均表现正常(A组)。
- 环形病灶平均SUVmax:B组4.5,C组4.2,D组4.8,E组5.9。
- 平均PSA水平:A组5.27,B组7.9,C组10.04,D组10.01,E组9.36。
- 11C-胆碱PET/CT在其他解剖部位(局部复发、淋巴结、骨、其他肝外部位)出现阳性发现与更高PSA相关(p=0.0285);单因素和多因素二元logistic回归分析中,PSA、环形SUVmax、局部复发、阳性淋巴结均与肝转移(D-E组)无显著关联(p>0.05);肝转移(D-E组)与骨病灶显著相关(p=0.00193)。
临床怎么用
- 作者认为在此临床情境下,核医学医师对肝脏示踪剂分布(摄取增高或减低)进行准确分析是必须的。
局限性
- 作者指出胆碱PET/CT存在技术局限。
- 作者认为真实发生率评估需更多研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: During our daily clinical practice using 11C-Choline PET/CT for restaging patients affected by relapsing prostate cancer (rPCa) we noticed an unusual but significant occurrence of hypodense hepatic lesions with a different tracer uptake. Thus, we decided to evaluate the possible correlation between rPCa and these lesions as possible hepatic metastases. MATERIALS AND METHODS: We retrospectively enrolled 542 patients diagnosed with rPCa in biochemical relapse after a radical treatment (surgery and/or radiotherapy). Among these, patients with a second tumor or other benign hepatic diseases were excluded. All patients underwent 11C-Choline PET/CT during the standard restaging workup of their disease. We analyzed CT images to evaluate the presence of hypodense lesions and PET images to identify the relative tracer uptake. In accordance to the subsequent oncological history, five clinical scenarios were recognized [Table 1]: normal low dose CT (ldCT) and normal tracer distribution (Group A); evidence of previously unknown hepatic round hypodense areas at ldCT with normal rim uptake (Group B); evidence of previously known hepatic round hypodense areas at ldCT stable over time and with normal rim uptake (Group C); evidence of previously known hepatic round hypodense areas at ldCT, in a previous PET/CT scan, with or without rim uptake and significantly changing over time in terms of size and/or uptake (Group D); evidence of hepatic round hypodense areas at ldCT with or without rim uptake confirmed as prostate liver metastases by histopathology, triple phase ceCT, ce-ultra sound (CEUS) and clinical/biochemical evaluation (Group E). We evaluated the correlation with PSA level at time of scan, rim SUVmax and association with local relapse or non-hepatic metastases (lymph nodes, bone, other parenchyma). RESULTS: Five hundred and forty-two consecutive patients were retrospectively enrolled. In 140 of the 542 patients more than one 11C-choline PET/CT had been performed. A total of 742 11C-Choline PET/CT scans were analyzed. Of the 542 patients enrolled, 456 (84.1%) had a normal appearance of the liver both at ldCT and PET (Group A). 19/542 (3,5%) belonged to Group B, 13/542 (2.4%) to Group C, 37/542 (6.8%) to Group D and 18/542 (3.3%) to Group E. Mean SUVmax of the rim was: 4.5 for Group B; 4.2 for Group C; 4.8 for Group D; 5.9 for Group E. Mean PSA level was 5.27 for Group A, 7.9 for Group B, 10.04 for Group C, 10.01 for Group D, 9.36 for Group E. Presence of positive findings at 11C-Choline PET/CT in any further anatomical area (local relapse, lymph node, bone, other extra hepatic sites) correlated with an higher PSA (p = 0.0285). In both the univariate and multivariate binary logistic regression analyses. PSA, SUVmax of the rim, local relapse, positive nodes were not associated to liver mets (Groups D-E) (p > 0.05). On the contrary, a significant correlation was found between the presence of liver metG (group D-E) and bone lesions (p= 0.00193). CONCLUSION: Our results indicate that liver metastases in relapsing prostate cancer may occur frequently. The real incidence evaluation needs more investigations. In this case and despite technical limitations, Choline PET/CT shows alterations of tracer distribution within the liver that could eventually be mistaken for simple cysts but can be suspected when associated to high trigger PSA, concomitant bone lesions or modification over time. In this clinical setting an accurate analysis of liver tracer distribution (increased or decreased uptake) by the nuclear medicine physician is, therefore, mandatory.
引用
- Ghedini P, Bossert I, Zanoni L, et al. Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis. Eur J Nucl Med Mol Imaging. 2017. PMID: 29192364. doi:10.1007/s00259-017-3888-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。